News & Media :: Vedanta Biosciences, Inc.

Oct 12, 2020

Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020

Recent News

Sep 30, 2020

Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients

Sep 16, 2020

Vedanta Biosciences Announces the Appointment of Jeffrey Silber, M.D. as Chief Medical Officer

Sep 11, 2020

First microbiome-based drug clears phase III, in clinical trial turnaround

Aug 5, 2020

Racing the clock to stop drug-resistant superbugs

View All News View All Press Releases